Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DHA in Pediatric NAFLD
NCT00885313Phase 2Completed
- Start
- Mar 2009
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of docosahexaenoic acid in non-alcoholic fatty liver disease (NAFLD) (3 arms). Primary endpoint: Liver status by liver biopsy (steatosis and fibrosis) at 24 months. Started Mar 2009; status: completed.
02
Drugs
docosahexaenoic acid
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT00885313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00885313.